{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/psychosis-schizophrenia/management/the-routine-schizophrenia-or-psychosis-review/","result":{"pageContext":{"chapter":{"id":"30f16f24-0127-53b7-bd08-c679a189090b","slug":"the-routine-schizophrenia-or-psychosis-review","fullItemName":"Scenario: The routine schizophrenia or psychosis review","depth":2,"htmlHeader":"<!-- begin field 8c64b4c1-de2a-42ef-b3bd-6c5512b50634 --><h2>Scenario: The routine schizophrenia or psychosis review</h2><!-- end field 8c64b4c1-de2a-42ef-b3bd-6c5512b50634 -->","summary":"Covers the routine mental and physical health review required for people with a psychotic disorder.","htmlStringContent":"<!-- begin item 86e2f936-7a20-4fee-b0b7-4f617e6fb7e2 --><!-- begin field f24992fb-1fbf-49ed-a32d-acbd00868167 --><p>From age 18 years onwards.</p><!-- end field f24992fb-1fbf-49ed-a32d-acbd00868167 --><!-- end item 86e2f936-7a20-4fee-b0b7-4f617e6fb7e2 -->","topic":{"id":"9b90da89-2ffd-5b6a-9fc6-ea342404d5d8","topicId":"fd02ebc3-0f02-42b5-8737-e0608ca4330d","topicName":"Psychosis and schizophrenia","slug":"psychosis-schizophrenia","lastRevised":"Last revised in November 2020","chapters":[{"id":"d60310a0-752b-5399-8488-a567bf6a3925","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"10869ad6-510d-54db-bc6a-ce3618a1c478","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"1025e31f-c89d-5344-b4ae-d5e8950a5c0e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"594160f5-1a9b-56f0-952c-5c400ea28785","slug":"changes","fullItemName":"Changes"},{"id":"e20c0ce8-30f6-5e09-81d1-3e6005f85efe","slug":"update","fullItemName":"Update"}]},{"id":"4c4f0990-85fa-5fc4-9a58-9f02a868a971","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"02637a5f-4552-5e73-9245-cf480497e9a5","slug":"goals","fullItemName":"Goals"},{"id":"8c88de52-9655-52d8-b302-67641ae05beb","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c6754da2-fd29-5d45-8097-40b8ec0589cd","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"31a210b8-403b-5530-b1ea-0b44a2595f07","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"c5630117-b04c-558a-b516-41c3eab9adbd","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"e9e078fd-a616-51bf-944f-2efbb2a01feb","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"99d1cff5-adca-5573-9fa8-58c2e9f937e0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"23ac3781-557a-57b8-95b5-83db37a53fda","slug":"definition","fullItemName":"Definition"},{"id":"3e7238cc-23d8-56f6-a8af-255ed6a876d7","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"9576e7c9-3a1e-57d3-bb86-a4e5e10462e1","slug":"prevalence","fullItemName":"Prevalence"},{"id":"b79b29b0-d7ad-5bad-87fd-e5a48ced5427","slug":"course-prognosis","fullItemName":"Course and prognosis"},{"id":"598444d7-6337-5133-a088-176b1f83ab01","slug":"complications","fullItemName":"Complications"}]},{"id":"a913b80f-eec4-5c47-9d9c-0b20f4648b73","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"e7897095-2be8-5df7-a7e3-c1060d4a453a","slug":"identifying-someone-at-risk-of-a-psychotic-disorder-or-experiencing-their-first-episode-of-psychosis","fullItemName":"Identifying someone at risk of a psychotic disorder or experiencing their first episode of psychosis"},{"id":"a8f36210-9cb6-590b-8e3d-7ddbc6d31e88","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"f86ff69c-c33e-5b8c-affa-04759f25bf5a","fullItemName":"Management","slug":"management","subChapters":[{"id":"34c0807e-9463-536b-9ff4-c3537046a6ba","slug":"primary-care-management","fullItemName":"Scenario: Primary care management"},{"id":"468f8b6f-bc79-5ecd-b1c2-d7ff27721abe","slug":"managing-relapse","fullItemName":"Scenario: Managing relapse"},{"id":"30f16f24-0127-53b7-bd08-c679a189090b","slug":"the-routine-schizophrenia-or-psychosis-review","fullItemName":"Scenario: The routine schizophrenia or psychosis review"},{"id":"c20919b9-2e4c-5c56-b3cd-7fb432199a8b","slug":"women-of-childbearing-age","fullItemName":"Scenario: Women of childbearing age"}]},{"id":"a9fe56bb-7ae3-5523-b0e2-5b7da5aa8439","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"f78f8497-f98b-5445-82fe-23a4ced38576","slug":"available-antipsychotics","fullItemName":"Available antipsychotics"},{"id":"05e42d64-ee5a-5c2b-8817-5fc77abb19ec","slug":"adverse-effects","fullItemName":"Adverse effects"},{"id":"25b3e7d5-bc3d-5749-9304-a717c1f4e386","slug":"interactions","fullItemName":"Interactions"},{"id":"ed339043-f5e2-5209-9ba0-cb06890e1050","slug":"monitoring","fullItemName":"Monitoring"}]},{"id":"7ae82132-000d-507c-b73d-542c43656041","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"1bf0a6af-76cf-5f6b-b7fb-4c746ff0f413","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"49b46ed4-7209-5c01-b07f-54117f9ad3c0","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a4647644-8726-5bfc-b471-6e157c3f10a3","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"a31ae673-4520-58d5-95ee-db2395fb5238","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"3beebe4c-a826-5b46-a8cd-a97fe8ec3b8b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"aaaadecf-036b-531f-a8bf-75fccd84219f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"49078833-deae-54f3-ad89-562370e4d181","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"f86ff69c-c33e-5b8c-affa-04759f25bf5a","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"d23d674c-5246-56c9-beb3-eab3d3a73064","slug":"routine-mental-physical-health-review","fullItemName":"Routine mental and physical health review","depth":3,"htmlHeader":"<!-- begin field 91f3b11a-01bf-4f49-874d-b0356fd7029d --><h3>How should I conduct a routine health review of someone with psychosis or schizophrenia?</h3><!-- end field 91f3b11a-01bf-4f49-874d-b0356fd7029d -->","summary":null,"htmlStringContent":"<!-- begin item e337d676-1ed2-4142-9f42-408338bc93a8 --><!-- begin field 079cc763-1ce8-40e1-a323-5ea3eaf788b0 --><ul><li><strong>Arrange review in primary care at least annually to assess the mental and physical health needs of the person.</strong><ul><li>The secondary care team should maintain responsibility for monitoring the person's physical health and the effects of any antipsychotic medication for the first 12 months of treatment, or until the person's condition has stabilised (whichever is the longest). After this, the responsibility for monitoring may be transferred to primary care, depending on locally agreed shared care guidelines or the person's care plan.</li></ul></li><li><strong>Develop and use practice case registers to monitor the physical and mental health of people with a psychotic disorder in primary care.</strong></li><li><strong>When carrying out a mental health review, a</strong><strong>ssess symptom control by:</strong><ul><li>Screening for <a class=\"topic-reference internal-reference\" href=\"/topics/psychosis-schizophrenia/background-information/definition/\">psychotic symptoms</a> (for example hallucinations and delusions) by asking:<ul><li>Do you hear voices when nobody is around?</li><li>Do you ever think that people are talking or gossiping about you, maybe even thinking about trying to get you?</li><li>Do you ever think that somehow people can pick up on what you are thinking or can manipulate what you are thinking?</li></ul></li><li>Asking about any deterioration in personal functioning such as changes in academic achievement, work, social interactions, or personal care.</li><li>Asking about co-existing depression and anxiety symptoms.<ul><li>If symptoms are not well-controlled, or anxiety or depression are present, refer the person to the key clinician or care coordinator identified in their care plan, for further management. Use clinical judgement to determine whether an <a class=\"topic-reference internal-reference\" href=\"/topics/psychosis-schizophrenia/management/primary-care-management/#primary-care-management\">assessment of the risk to the person or others</a> is necessary and if a high risk is identified, urgently refer the person to the crisis resolution and home treatment team. </li></ul></li></ul></li><li><strong>When carrying out a physical health review:</strong><ul><li><strong>Review adherence to treatment and ask about any symptoms that may be due to <a class=\"topic-reference internal-reference\" href=\"/topics/psychosis-schizophrenia/prescribing-information/adverse-effects/\">adverse effects</a></strong> (for example sedation, extrapyramidal symptoms).<ul><li>Arrange specialist review if adherence with medication is poor, symptoms are poorly controlled, or adverse effects are poorly tolerated.</li><li>Ask about symptoms of raised prolactin (such as low libido, sexual dysfunction, menstrual abnormalities [amenorrhoea or oligomenorrhoea], gynaecomastia, and galactorrhoea) particularly if the person is taking a first generation antipsychotic or risperidone.</li><li>Clozapine — people taking clozapine are managed exclusively in secondary care. Clozapine can cause neutropenia or agranulocytosis, and frequent monitoring of the full blood count is required (weekly for 18 weeks after starting treatment, then every 2 weeks for the next 18 weeks, and then every 4 weeks thereafter). This is carried out by the specialist clozapine monitoring service.</li></ul></li><li><strong>Ensure that there are arrangements in place for </strong><a class=\"topic-reference internal-reference\" href=\"/topics/psychosis-schizophrenia/prescribing-information/monitoring/\">monitoring</a> <strong>antipsychotics</strong> <strong>(if applicable).</strong></li><li><strong>Ask about alcohol intake and substance misuse. </strong>For more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/alcohol-problem-drinking/\">Alcohol - problem drinking</a> and <a class=\"topic-reference external-reference\" href=\"/topics/opioid-dependence/\">Opioid dependence</a>.<br><strong>Encourage people who smoke to stop.</strong> <strong>Offer referral for smoking cessation or specialist treatment where appropriate. </strong>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/smoking-cessation/\">Smoking cessation</a>.<ul><li>Assess for respiratory conditions such as chronic obstructive pulmonary disorder (COPD) if appropriate. For further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/\">Chronic obstructive pulmonary disease</a>.</li><li>Note that smoking enhances the metabolism of olanzapine and clozapine and reducing/stopping smoking may, therefore, affect plasma levels of these drugs and precipitate the requirement for dose adjustment.</li></ul></li><li><strong>Ask about the person's diet and level of physical activity, check the person's weight and measure their waist circumference </strong><strong>(plot both on a chart), and manage obesity.</strong><ul><li>For more information see, the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a>.</li><li>Note that people with psychosis or schizophrenia, especially those taking antipsychotics, should have been offered a combined healthy eating and physical activity programme by their mental healthcare provider. </li></ul></li><li><strong>Measure the person's pulse and blood pressure, and assess and manage the person's cardiovascular risk.</strong> For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/\">CVD risk assessment and management</a>.</li><li><strong>Perform the following blood tests:</strong><ul><li>Fasting glucose, HbA1c.</li><li>Lipid profile.</li><li>Urea and electrolytes.</li><li>Full blood count.</li><li>Liver function tests.</li><li>Prolactin (annual prolactin measurement is not required if the person is taking aripiprazole, clozapine, quetiapine, or olanzapine).</li></ul></li></ul></li><li><strong>Manage as appropriate people identified as having hypertension, abnormal lipid levels, obesity (or those at risk of obesity), diabetes (or risk of diabetes as indicated by abnormal blood glucose levels). </strong>For more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/hypertension-not-diabetic/\">Hypertension - not diabetic</a> , <a class=\"topic-reference external-reference\" href=\"/topics/lipid-modification-cvd-prevention/\">Lipid modification - CVD prevention</a>, <a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-2/\">Diabetes - type 2</a>.</li><li><strong>Carry out an electrocardiograph (ECG) </strong>if the person is taking haloperidol, pimozide or sertindole if they have had a previous ECG abnormality, or if they have an additional risk factor for QT prolongation (for example taking another medication that can increase the QT interval such as erythromycin, co-trimoxazole, or pregabalin). These drugs have been associated with QTc prolongation.<ul><li>A QT interval of >450 milliseconds may be cause for concern, while a QT interval > 500 milliseconds should prompt the seeking of specialist advice.</li></ul></li><li><strong>Send a copy of the results of the annual physical health review to the person's care coordinator and/or psychiatrist.</strong></li><li><strong>Attempt to make contact with people who do not attend a review appointment (within 14 days).</strong><ul><li>If it is not possible to make contact despite reasonable efforts to do so, inform the person's care coordinator (who may be their psychiatrist, community psychiatric nurse, or social worker).</li></ul></li></ul><!-- end field 079cc763-1ce8-40e1-a323-5ea3eaf788b0 --><!-- end item e337d676-1ed2-4142-9f42-408338bc93a8 -->","subChapters":[{"id":"1d4e5b6a-67de-5d70-921f-ee4b07efeff5","slug":"basis-for-recommendation-6fa","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field f1e4fe3e-a46a-4734-8b3c-ab4f00e2e089 --><h4>Basis for recommendation</h4><!-- end field f1e4fe3e-a46a-4734-8b3c-ab4f00e2e089 -->","summary":null,"htmlStringContent":"<!-- begin item 6fae12d8-f1ae-4d73-934f-ab4f00e2dfd3 --><!-- begin field 9ee8033d-3c12-4202-98dd-ab4f00e2e089 --><p>The recommendations on carrying out a routine mental and physical health review in primary care for people with a psychotic disorder are largely based on expert opinion within the National Institute for Health and Care Excellence (NICE) guideline <em>Psychosis and schizophrenia in adults: prevention and management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/psychosis-schizophrenia/references/\">NICE, 2014</a>].</p><h5>Assessing adverse effects of antipsychotic drugs</h5><ul><li>The recommendation to specifically ask about symptoms of raised prolactin is based on expert opinion from the Maudsley prescribing guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psychosis-schizophrenia/references/\">Taylor, 2018</a>]. Hyperprolactinaemia may be asymptomatic and people who are taking antipsychotics often do not spontaneously report these adverse effects.</li></ul><h5>Assessing smoking status</h5><ul><li>Information about the effect of smoking on olanzapine and clozapine metabolism reflects advice provided by the Medicines and Healthcare products Regulatory Agency (MHRA) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psychosis-schizophrenia/references/\">MHRA, 2009a</a>]. Smoking induces the metabolism of olanzapine and clozapine because polycyclic aromatic hydrocarbons found in tobacco smoke are potent inducers of hepatic cytochrome P450. Dose may be needed if the person stops (or starts) smoking during treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psychosis-schizophrenia/references/\">Joint Formulary Committee, 2020</a>]. CKS pragmatically recommends that any dose adjustments should be overseen by secondary care.</li></ul><h5>Carrying out an electrocardiograph (ECG)</h5><ul><li>The recommendation to perform an ECG for people taking haloperidol, pimozide and sertindole is based on expert opinion published in the Maudsley prescribing guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psychosis-schizophrenia/references/\">Taylor, 2018</a>]. Many antipsychotics are associated with ECG changes and prolongation of the QT interval. Haloperidol, pimozide, and sertindole are associated with the highest risk (QTc prolongation is usually more than 20 milliseconds at normal clinical doses) and annual ECG monitoring is mandatory for these drugs. A previous expert reviewer of this CKS topic stated that QT prolongation is greater than 450 milliseconds is a cause for concern and that specialist advice from a consultant psychiatrist should be sought if QT interval is greater than 500 milliseconds.</li></ul><!-- end field 9ee8033d-3c12-4202-98dd-ab4f00e2e089 --><!-- end item 6fae12d8-f1ae-4d73-934f-ab4f00e2dfd3 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}